Genfit (GNFT) Stock Overview
A late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
GNFT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Genfit S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €5.18 |
| 52 Week High | €5.41 |
| 52 Week Low | €2.62 |
| Beta | 0.87 |
| 1 Month Change | 11.40% |
| 3 Month Change | 51.20% |
| 1 Year Change | 43.29% |
| 3 Year Change | 35.32% |
| 5 Year Change | 15.63% |
| Change since IPO | -60.03% |
Recent News & Updates
Recent updates
These Analysts Just Made An Downgrade To Their Genfit S.A. (EPA:GNFT) EPS Forecasts
Sep 23
Some Analysts Just Cut Their Genfit S.A. (EPA:GNFT) Estimates
Jul 16Shareholders Will Probably Not Have Any Issues With Genfit S.A.'s (EPA:GNFT) CEO Compensation
Jun 11Improved Revenues Required Before Genfit S.A. (EPA:GNFT) Stock's 29% Jump Looks Justified
May 06Solid Earnings Reflect Genfit's (EPA:GNFT) Strength As A Business
May 02These 4 Measures Indicate That Genfit (EPA:GNFT) Is Using Debt Reasonably Well
Apr 29Genfit S.A. (EPA:GNFT) Not Doing Enough For Some Investors As Its Shares Slump 25%
Nov 16We Think Shareholders Should Be Aware Of Some Factors Beyond Genfit's (EPA:GNFT) Profit
Sep 27Genfit S.A. (EPA:GNFT) Held Back By Insufficient Growth Even After Shares Climb 26%
Sep 26Growth Investors: Industry Analysts Just Upgraded Their Genfit S.A. (EPA:GNFT) Revenue Forecasts By 28%
Sep 24Genfit (EPA:GNFT) Seems To Use Debt Quite Sensibly
Sep 22Genfit S.A.'s (EPA:GNFT) Price Is Right But Growth Is Lacking After Shares Rocket 28%
May 23Genfit S.A.'s (EPA:GNFT) 26% Price Boost Is Out Of Tune With Revenues
Jan 03Health Check: How Prudently Does Genfit (EPA:GNFT) Use Debt?
Sep 22Revenue Downgrade: Here's What Analysts Forecast For Genfit S.A. (EPA:GNFT)
Jul 05Genfit S.A. (EPA:GNFT) Investors Are Less Pessimistic Than Expected
Jun 23We Think Genfit (EPA:GNFT) Can Manage Its Debt With Ease
Dec 28New Forecasts: Here's What Analysts Think The Future Holds For Genfit S.A. (EPA:GNFT)
Sep 30Downgrade: Here's How Analysts See Genfit S.A. (EPA:GNFT) Performing In The Near Term
Jun 29Genfit's(EPA:GNFT) Share Price Is Down 85% Over The Past Five Years.
Mar 14Shareholder Returns
| GNFT | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -2.1% | -12.3% | 1.4% |
| 1Y | 43.3% | 320.9% | 8.9% |
Return vs Industry: GNFT underperformed the French Biotechs industry which returned 364% over the past year.
Return vs Market: GNFT exceeded the French Market which returned 8.6% over the past year.
Price Volatility
| GNFT volatility | |
|---|---|
| GNFT Average Weekly Movement | 6.4% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 10.1% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: GNFT has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: GNFT's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 188 | M. Prigent | www.genfit.com |
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
Genfit S.A. Fundamentals Summary
| GNFT fundamental statistics | |
|---|---|
| Market cap | €257.94m |
| Earnings (TTM) | -€38.76m |
| Revenue (TTM) | €45.13m |
Is GNFT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GNFT income statement (TTM) | |
|---|---|
| Revenue | €45.13m |
| Cost of Revenue | €0 |
| Gross Profit | €45.13m |
| Other Expenses | €83.89m |
| Earnings | -€38.76m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.78 |
| Gross Margin | 100.00% |
| Net Profit Margin | -85.89% |
| Debt/Equity Ratio | 255.9% |
How did GNFT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/05 07:27 |
| End of Day Share Price | 2026/01/05 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genfit S.A. is covered by 15 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Geoffrey Meacham | BofA Global Research |
| Arnaud Cadart | CIC Market Solutions (ESN) |
| Alethia Young | Deutsche Bank |